CAI – Caris Life Sciences Inc
CAI — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
6.26
Margin Of Safety %
-4
Put/Call OI Ratio
0.99
EPS Next Q Diff
-0.24
EPS Last/This Y
3.37
EPS This/Next Y
0.23
Price
16.93
Target Price
33
Analyst Recom
1.27
Performance Q
-39.98
Upside
-496.5%
Beta
Ticker: CAI
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | CAI | 18.99 | 0.97 | 28.06 | 8859 |
| 2026-03-10 | CAI | 18.52 | 0.77 | 0.18 | 7944 |
| 2026-03-11 | CAI | 18.61 | 0.74 | 0.75 | 8120 |
| 2026-03-12 | CAI | 17.68 | 0.75 | 673.00 | 8144 |
| 2026-03-13 | CAI | 17.69 | 0.75 | 673.33 | 8144 |
| 2026-03-17 | CAI | 18.53 | 0.78 | 0.18 | 8353 |
| 2026-03-18 | CAI | 18.45 | 0.78 | 0.00 | 8335 |
| 2026-03-19 | CAI | 18.79 | 0.79 | 0.20 | 8257 |
| 2026-03-20 | CAI | 18.49 | 0.79 | 0.75 | 8255 |
| 2026-03-23 | CAI | 19.34 | 1.01 | 0.46 | 6588 |
| 2026-03-24 | CAI | 19.21 | 1.01 | 0.00 | 6592 |
| 2026-03-25 | CAI | 18.53 | 1.00 | 999.99 | 6610 |
| 2026-03-26 | CAI | 18.33 | 0.99 | 0.67 | 6558 |
| 2026-03-27 | CAI | 16.94 | 0.99 | 0.13 | 6568 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | CAI | 19.00 | - | 184.8 | - |
| 2026-03-10 | CAI | 18.52 | - | 65.1 | - |
| 2026-03-11 | CAI | 18.60 | - | 66.8 | - |
| 2026-03-12 | CAI | 17.68 | - | 63.5 | - |
| 2026-03-13 | CAI | 18.15 | - | 68.1 | 0.15 |
| 2026-03-17 | CAI | 18.52 | - | 78.7 | 0.15 |
| 2026-03-18 | CAI | 18.45 | - | 80.4 | 0.15 |
| 2026-03-19 | CAI | 18.81 | - | 82.1 | 0.15 |
| 2026-03-20 | CAI | 18.41 | - | 79.1 | 0.15 |
| 2026-03-23 | CAI | 19.23 | - | 84.1 | 0.15 |
| 2026-03-24 | CAI | 19.21 | - | 80.7 | 0.15 |
| 2026-03-25 | CAI | 18.56 | - | 78.1 | 0.15 |
| 2026-03-26 | CAI | 18.33 | - | 79.8 | 0.15 |
| 2026-03-27 | CAI | 16.93 | - | 75.0 | 0.15 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | CAI | -0.04 | 14.79 | 5.04 |
| 2026-03-10 | CAI | -0.04 | 14.79 | 5.04 |
| 2026-03-11 | CAI | -0.04 | 14.79 | 5.40 |
| 2026-03-12 | CAI | -0.04 | 14.79 | 5.40 |
| 2026-03-13 | CAI | -0.04 | 14.79 | 5.40 |
| 2026-03-17 | CAI | -0.04 | 14.79 | 5.40 |
| 2026-03-18 | CAI | -0.04 | 14.79 | 5.40 |
| 2026-03-19 | CAI | -0.04 | 14.79 | 5.40 |
| 2026-03-20 | CAI | -0.04 | 14.79 | 5.40 |
| 2026-03-23 | CAI | -0.04 | 14.77 | 5.40 |
| 2026-03-24 | CAI | -0.04 | 14.77 | 5.40 |
| 2026-03-25 | CAI | -0.04 | 14.77 | 6.26 |
| 2026-03-26 | CAI | -0.04 | 14.77 | 6.26 |
| 2026-03-27 | CAI | -0.04 | 14.77 | 6.26 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.28
Avg. EPS Est. Current Quarter
-0.03
Avg. EPS Est. Next Quarter
0.04
Insider Transactions
-0.04
Institutional Transactions
14.77
Beta
Average Sales Estimate Current Quarter
210
Average Sales Estimate Next Quarter
248
Fair Value
16.25
Quality Score
43
Growth Score
Sentiment Score
26
Actual DrawDown %
60.2
Max Drawdown 5-Year %
Target Price
33
P/E
Forward P/E
42.34
PEG
P/S
5.9
P/B
8.3
P/Free Cash Flow
80.92
EPS
-1.92
Average EPS Est. Cur. Y
0.15
EPS Next Y. (Est.)
0.38
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-66.25
Relative Volume
1.47
Return on Equity vs Sector %
-120.5
Return on Equity vs Industry %
-104.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.1
EBIT Estimation
75
◆
CAI
Healthcare
$16.95
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
34.5
Range 1M
7.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
138.7%
EPS NY
153.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+7% upside
Upside
+7%
Quality
43
MoS
-4%
Caris Life Sciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1846
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
CAI
Latest News
—
Caricamento notizie per CAI…
stock quote shares CAI – Caris Life Sciences Inc Stock Price stock today
news today CAI – Caris Life Sciences Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch CAI – Caris Life Sciences Inc yahoo finance google finance
stock history CAI – Caris Life Sciences Inc invest stock market
stock prices CAI premarket after hours
ticker CAI fair value insiders trading